Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$0.86
$0.03(2.88%)
At close: 4:00 PM EDT
$0.86
$0.03(2.88%)
Day’s Range― - ―
52-Week Range$0.71 - $3.06
Previous Close$1.07
Volume153.44K
Average Volume (3M)111.16K
Market Cap
$24.83M
Enterprise Value$57.74M
Total Cash (Recent Filing)$94.36K
Total Debt (Recent Filing)$1.76M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding26,694,475
10 Day Avg. Volume66,461
30 Day Avg. Volume111,163
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap2.33
Enterprise Value/Revenue-72.54
Enterprise Value/Gross Profit-72.54
Enterprise Value/Ebitda-7.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Improved LeverageThe sharp reduction in leverage gives ABVC a stronger balance-sheet position than in 2024 and reduces debt-related pressure on future capital allocation. Although losses remain substantial, lower debt relative to equity provides greater flexibility while the company advances its development pipeline.
Retained BioKey OwnershipThe completed separation created an independently reporting BioKey entity while ABVC retained approximately 85% ownership. This structure preserves substantial exposure to the subsidiary’s future development while distributing a direct interest to ABVC shareholders and clarifying the asset’s corporate identity.
Broad Development PipelineA pipeline spanning CNS disorders, oncology, and ophthalmology gives ABVC multiple therapeutic areas in which to pursue clinical progress and partnering opportunities. The company’s licensing-oriented model can create milestone and royalty potential if candidates advance toward regulatory approval and commercialization.
Bears Say
Deep Operating LossesABVC is generating large operating and net losses, indicating that its current development activities are not yet supported by profitable operations. Persistent losses can erode equity, limit internal reinvestment capacity, and increase dependence on successful clinical, regulatory, or financing outcomes.
Persistent Cash BurnNegative operating and free cash flow show that ABVC is not currently self-funding its activities. Continued cash burn creates an ongoing need for external funding or transaction proceeds, while declining free cash flow versus the prior period could constrain the company’s ability to sustain development without additional capital.
Unestablished Revenue BaseABVC lacks a consistent operating revenue base, with zero revenue in the last annual period and negative TTM revenue reported. This makes financial performance highly dependent on pipeline transactions, licensing milestones, or capital raises rather than recurring product sales, reducing earnings visibility.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.71 and its highest was $3.06 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $24.83M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 24 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 26,694,475 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.35% Mutual Funds
0.14% Other Institutional Investors
96.38% Public Companies and
Individual Investors